SGNPDL 1V
Alternative Names: PF-08046054; SGN-PDL1VLatest Information Update: 15 Dec 2023
At a glance
- Originator Seagen
- Class Antineoplastics; Auristatins; Drug conjugates; Immunoconjugates; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Cell death stimulants; Mitosis inhibitors; Programmed cell death-1 ligand-1 inhibitors; Tubulin polymerisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 14 Dec 2023 Seagen has been acquired by Pfizer
- 09 Feb 2022 Seagen plans a first-in-human phase I trial in Solid tumours in 2022 (NCT05208762)
- 22 Jan 2022 Phase-I clinical trials in Solid tumours (Monotherapy, Late-stage disease, Second-line therapy or greater, Inoperable/Unresectable, Metastatic disease) in USA (IV) (NCT05208762)